News Releases


 

Feb 20, 2018

Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent

Feb 15, 2018

Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018

Feb 7, 2018

Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Jan 26, 2018

Insmed Announces Closing of Public Offering

Jan 24, 2018

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 23, 2018

Insmed Announces Pricing of Public Offering of Convertible Senior Notes

Jan 22, 2018

Insmed Announces Proposed Public Offering of Convertible Senior Notes

Jan 3, 2018

Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations

Nov 28, 2017

Insmed to Present at the Nasdaq 37th Annual Investor Conference

Nov 22, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)